A multi-strategy platform for quality control and Q-markers screen of Chaiqin chengqi decoction
- PMID: 33740732
- DOI: 10.1016/j.phymed.2021.153525
A multi-strategy platform for quality control and Q-markers screen of Chaiqin chengqi decoction
Abstract
Background: Acute pancreatitis (AP) is an inflammatory disorder of the pancreas that is associated with substantial morbidity and mortality. Chaiqin chengqi decoction (CQCQD) has been proven clinically to be an effective treatment for AP for decades in West China Hospital. Quality control for CQCQD containing many hundreds of characteristic phytochemicals poses a challenge for developing robust quality assessment metrics.
Purpose: To evaluate quality consistency of CQCQD with a multi-strategy based analytical method, identify potential quality-markers (Q-markers) based on drug properties and effect characteristics, and endeavor to establish CQCQD as a globally-accepted medicine.
Methods: A typical analysis of constitutive medicinal plant materials was performed following the Chinese Pharmacopoeia. The extraction process was optimized through an orthogonal array (L9(34)) to evaluate three levels of liquid to solid ratio, soaking time, duration of extraction, and the number of extractions. An ultra-high-performance liquid chromatography (UHPLC) fingerprinting combined with absolute quantitation of multi chemical marker compounds, coupled with similarity, hierarchical clustering analysis (HCA), and principal component analyses (PCA) were performed to evaluate 10 batches of CQCQD. On the basis of systematic analysis of fundamental features of CQCQD in treating AP, the potential Q-marker screen was proposed through detection of quality transfer and efficacy for chemical markers. UHPLC coupled with quadrupole orbitrap mass spectrometry were used to determine compounds in medicinal materials, decoctions and plasma. Network pharmacology and taurolithocholic acid 3-sulfate induced pancreatic acinar cell death were used to evaluate the correlation between chemical markers and anti-pancreatitis activity. A cerulein induced AP murine model was used to validate quality assessed CQCQD batches at clinically-equivalent dose. The effective content of chemical markers was predicted using linear regression analysis on quantitative information between validated batches and the other batches.
Results: The chemical markers and other physical and chemical indices in the original materials met Chinese Pharmacopoeia standards. A total of 22 co-existing fingerprint peaks were selected and the similarity varied between 0.946 and 0.990. Batch D10 possessed the highest similarity index. HCA classified the 10 batches into 2 main groups: 7 batches represented by D10 and 3 batches represented by D1. During the initial Q-marker screen stage, 22 compounds were detected in both plant materials and decoctions, while 13 compounds were identified in plasma. Network pharmacology predicted the potential targets and pathway of AP related to the 22 compounds. All 10 batches showed reduced necrosis below 60% with the best effect achieved by D10 (~40%). The spectrum-efficacy relationship analyzed by Pearson correlation analysis indicated that emodin, rhein, aloe emodin, geniposide, hesperridin, chrysin, syringin, synephrine, geniposidic acid, magnolol, physcion, sinensetin, and baicalein showed positive correlation with pancreatic acinar cell death protection. Similar to the in vitro evaluation, batch D10 significantly reduced total histopathological scores and biochemical severity indices at a clinically-equivalent dose but batch D1 did not. The content of naringin, narirutin and baicalin in batches D1, D5 and D9 consistently exceeds the upper limit of the predicted value. Eight markers whose lower limit is predicted to be close to 0 contributed less to the material basis for AP protection.
Conclusion: Despite qualified materials used for CQCQD preparation, the clinical effect depends on appropriate content range of Q-markers. Emodin, rhein, aloe emodin, magnolol, hesperidin, synephrine, baicalein, and geniposide are considered as vital Q-markers in the primary screen. This study proposed a feasible platform for producing highly consistent batches of CQCQD in future study.
Keywords: Acute pancreatitis; Chaiqin chengqi decoction; Chemometrics; Q-marker; Quality control.
Copyright © 2021 Elsevier GmbH. All rights reserved.
Similar articles
-
Chaiqin chengqi decoction alleviates severity of acute pancreatitis via inhibition of TLR4 and NLRP3 inflammasome: Identification of bioactive ingredients via pharmacological sub-network analysis and experimental validation.Phytomedicine. 2020 Dec;79:153328. doi: 10.1016/j.phymed.2020.153328. Epub 2020 Sep 1. Phytomedicine. 2020. PMID: 33007730
-
Chaiqin chengqi decoction ameliorates acute pancreatitis in mice via inhibition of neuron activation-mediated acinar cell SP/NK1R signaling pathways.J Ethnopharmacol. 2021 Jun 28;274:114029. doi: 10.1016/j.jep.2021.114029. Epub 2021 Mar 14. J Ethnopharmacol. 2021. PMID: 33731310
-
Chaiqin chengqi decoction alleviates acute pancreatitis by targeting gasdermin D-mediated pyroptosis.J Ethnopharmacol. 2024 Jan 10;318(Pt A):116920. doi: 10.1016/j.jep.2023.116920. Epub 2023 Jul 21. J Ethnopharmacol. 2024. PMID: 37480969
-
From quality markers to data mining and intelligence assessment: A smart quality-evaluation strategy for traditional Chinese medicine based on quality markers.Phytomedicine. 2018 May 15;44:109-116. doi: 10.1016/j.phymed.2018.01.017. Epub 2018 Jan 31. Phytomedicine. 2018. PMID: 29426601 Review.
-
Novel strategy for quality consistency evaluation of Chinese medicine "YIQING" tablet that combines the simultaneous quantification and screening of ten bioactive constituents.J Sep Sci. 2017 Aug;40(15):3064-3073. doi: 10.1002/jssc.201700291. Epub 2017 Jun 28. J Sep Sci. 2017. PMID: 28590083 Review.
Cited by
-
Transcriptomics and Network Pharmacology Reveal the Protective Effect of Chaiqin Chengqi Decoction on Obesity-Related Alcohol-Induced Acute Pancreatitis via Oxidative Stress and PI3K/Akt Signaling Pathway.Front Pharmacol. 2022 Jun 8;13:896523. doi: 10.3389/fphar.2022.896523. eCollection 2022. Front Pharmacol. 2022. PMID: 35754467 Free PMC article.
-
Neurokinin 1 receptor inhibition alleviated mitochondrial dysfunction via restoring purine nucleotide cycle disorder driven by substance P in acute pancreatitis.Acta Pharm Sin B. 2025 Jun;15(6):3025-3040. doi: 10.1016/j.apsb.2025.03.037. Epub 2025 Mar 18. Acta Pharm Sin B. 2025. PMID: 40654355 Free PMC article.
-
Hesperidin Alleviates Acute Necrotizing Pancreatitis by Activating SIRT1 - Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.Comb Chem High Throughput Screen. 2024;27(12):1745-1757. doi: 10.2174/1386207326666230803140408. Comb Chem High Throughput Screen. 2024. PMID: 37534793
-
An Integrated Strategy to Identify and Quantify the Quality Markers of Xinkeshu Tablets Based on Spectrum-Effect Relationship, Network Pharmacology, Plasma Pharmacochemistry, and Pharmacodynamics of Zebrafish.Front Pharmacol. 2022 May 23;13:899038. doi: 10.3389/fphar.2022.899038. eCollection 2022. Front Pharmacol. 2022. PMID: 35677447 Free PMC article.
-
Zengye Decoction Attenuated Severe Acute Pancreatitis Complicated with Acute Kidney Injury by Modulating the Gut Microbiome and Serum Amino Acid Metabolome.Evid Based Complement Alternat Med. 2022 May 9;2022:1588786. doi: 10.1155/2022/1588786. eCollection 2022. Evid Based Complement Alternat Med. 2022. PMID: 35586694 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous